NexMed Engages FTN Equity Capital Markets Corp.

EAST WINDSOR, N.J.--(BUSINESS WIRE)--NexMed, Inc. (Nasdaq: NEXM), a developer of innovative transdermal products based on the Company’s proprietary NexACT^® drug delivery technology, announced today that it has retained FTN Equity Capital Markets Corp., in New York City, as its financial advisor to assist the Company in exploring and evaluating strategic alternatives.

“We are pleased to have retained FTN, a firm which is very familiar with our company, and we look forward to considering the various opportunities available to us, including merger or acquisition transactions. Our ultimate goal is to enhance value and maximize the return on investment for our shareholders.”

Vivian Liu, NexMed’s Chief Executive Officer stated, “We are pleased to have retained FTN, a firm which is very familiar with our company, and we look forward to considering the various opportunities available to us, including merger or acquisition transactions. Our ultimate goal is to enhance value and maximize the return on investment for our shareholders.”

NexMed advised that there can be no assurances that this process will result in any specific transactions and no decision has been made to pursue any strategic alternative at this time. NexMed does not expect to disclose any further development with respect to the exploration of strategic alternatives unless and until its Board of Directors has approved a transaction or other strategic alternative.

About NexMed

NexMed’s pipeline includes its innovative topical onychomycosis treatment, which is licensed to Novartis for global development, a late stage alprostadil treatment for erectile dysfunction, a Phase 2 treatment for female sexual arousal disorder, and an early stage treatment for psoriasis. For further information about NexMed, go to www.nexmed.com.

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described, including, but not limited to, entering into a strategic transaction, obtaining regulatory approval for its products under development, entering into partnering agreements, pursuing growth opportunities, and/or other factors, some of which are outside the control of the Company.